Physician profile
David Bonnet
NPI 1982612180
$4,725.84
in general payments reported to CMS, 2019-2025
42 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $794 · 2021: $853 · 2022: $669 · 2023: $561 · 2024: $526 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,165.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.75 | 2019-2025 | Jardiance |
| Abbvie INC. | $379.33 | 2020-2025 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $365.23 | 2019-2023 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $282.36 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $223.53 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Merck Sharp & Dohme LLC | $223.38 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genentech USA, INC. | $159.59 | 2019-2022 | |
| Novo Nordisk INC | $140.52 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $122.77 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $95.18 | 2020-2021 | |
| Validus Pharmaceuticals LLC | $89.60 | 2025 | Raldesy, Equetro |
| Sanofi Pasteur INC. | $83.50 | 2019-2025 | |
| Eisai INC. | $70.96 | 2020-2021 | |
| Amarin Pharma, INC. | $68.44 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bonnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.